LXR-regulated proteins The key to unlocking cholesterol homeostasis
| Authors |
|
|---|---|
| Supervisors | |
| Cosupervisors |
|
| Award date | 18-03-2025 |
| ISBN |
|
| Number of pages | 133 |
| Organisations |
|
| Abstract |
Our body needs to manage cholesterol carefully. Too much can lead to life-threatening diseases like atherosclerosis, while too little disrupts essential functions. At the heart of this balance are the liver X receptors (LXRs), which help reduce cholesterol buildup by regulating how cells absorb and release it. This research reveals how LXRs influence not only cholesterol levels but also the composition of fats in cell membranes, which is crucial for keeping cells healthy and stable.
We identified new targets of LXR regulation with important implications for health. One discovery is TMEM86a, a protein that controls special fats called lysoplasmalogens, which maintain the integrity of cell membranes. Another key player, EEPD1, helps immune cells called macrophages expel excess cholesterol. We also explored IDOL, a protein that limits cholesterol uptake by breaking down LDL receptors. Earlier findings suggest that blocking IDOL could become a powerful treatment for high cholesterol and cardiovascular diseases. We discovered several potential IDOL inhibitors that may serve as the basis for future cholesterol-lowering treatments. This thesis not only deepens our understanding of how LXRs regulate cholesterol and lipid metabolism but also opens the door to new therapeutic strategies for cardiovascular and neurodegenerative diseases. If you're curious about the hidden mechanisms that keep our bodies in balance, and how we might harness them to fight disease, this work provides valuable insights and future directions for medical science. |
| Document type | PhD thesis |
| Language | English |
| Downloads |
Thesis (complete)
(Embargo up to 2027-03-18)
Chapter 5: Discovery of novel small molecules targeting idol reveal potential therapeutic avenues for regulation of cholesterol metabolism regulation
(Embargo up to 2027-03-18)
|
| Permalink to this page | |